JP2001212115A - Biomedical photometer - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a biomedical photometer which enables not only specifying of an abnormal part but also monitoring of changes in the residue of oxygen of the abnormal part. SOLUTION: In a biomedical photometer which irradiates a specimen with light from a plurality of light irradiation positions to detect light passing through the specimen at a plurality of photodetecting positions and processes biomedical information at a plurality of measuring points determined by the light irradiation positions and the photodetecting positions to calculate the concentration of hemoglobin or the like, a processing part 19 calculates a relative change in the concentration of hemoglobin at each measuring point on the time base to specify any probable abnormal part from the calculated concentration of hemoglobin while calculating the residual time of oxygen at the part to be outputted to an input/output part 20.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to transmitted light from a living body,
The present invention relates to a biological optical measurement device that measures reflected light or scattered light to measure information of a living body, in particular, blood circulation and changes in blood hemoglobin. The present invention relates to a biological light measurement device useful as a monitor or a diagnostic device when used in combination with a living body.

[0002]

2. Description of the Related Art Conventionally, transmitted light from a living body is measured,
An oxygen monitor that measures the amount of oxygen in blood simply and without harm to a living body is known. However, the conventional oxygen monitor measures only one place, and a multipoint measuring apparatus for measuring the inside of a living body has been desired in fields such as clinical medicine and brain science. In response to this demand, there has been proposed an apparatus for measuring the inside of a living body by irradiating the living body with light of visible to infrared wavelengths from a plurality of irradiation positions and detecting light transmitted through the living body at a plurality of detection positions. (For example, Japanese Patent Application No. 9-98972, Japanese Patent Application Laid-Open No. 9-149903, etc.).

[0003] This device is called a biological optical measurement device or an optical topography device, and based on light intensity signals measured at a plurality of measurement points, the relative change amount of the blood oxyhemoglobin / deoxyhemoglobin concentration at each measurement point. Is calculated, and a hemoglobin distribution map called a topography is displayed.

[0004] In such a topography, a change or an abnormality occurring in the living body can be known from a state of a change in the hemoglobin concentration. However, the topography is changed because the position of a measurement point is drawn as coordinates. The site was difficult to identify, and diagnosis from topography was difficult.

[0005] Some lesions, such as malignant tumors, can be distinguished from normal tissues due to differences in the manner of change in hemoglobin concentration. It was difficult to identify differences in temporal changes.

Further, it has been reported that radiotherapy for malignant tumors is most effective when the oxygen concentration of the malignant tumors is high, and by appropriately selecting the time from oxygen load to irradiation. It is said that cytotoxicity of malignant tumors can be effectively performed by minimizing the damage effect on normal tissues. , 81-90
P. 1999). However, there was no way to know the timing of radiation irradiation without fail, and had to rely on experience.

[0007]

SUMMARY OF THE INVENTION Accordingly, an object of the present invention is to provide a living body light measuring device which can specify a portion where a change has occurred. Another object of the present invention is to provide a biological light measurement device capable of delineating biological information from a site where a change has occurred, for example, a change in hemoglobin concentration over time. Still another object of the present invention is to provide a biological light measurement device capable of calculating or displaying the remaining time of oxygen for a specific site.

[0008]

According to the present invention, there is provided a living body light measuring apparatus for irradiating a living body with light having different modulations from a plurality of light irradiation positions. A light detection unit that detects transmitted light at a plurality of detection positions and outputs an electric signal corresponding to the detected light amount for a plurality of measurement sites determined in relation to a light irradiation position; and an electric signal from the light detection unit. Signal processing means for calculating the hemoglobin concentration for each of the measurement sites based on the following, and means for displaying the calculation result of the signal processing means, wherein the display means displays the time course of the hemoglobin concentration for each measurement site Means are provided.

By displaying the time lapse of each measurement site, it is possible to distinguish between tissues having different hemoglobin concentrations over time, that is, normal tissues and malignant tumors. still,
In this specification, light transmitted through a living body includes transmitted light, reflected light, and all light detected by a photodetector after interacting with a living body without being particularly distinguished from scattered light. .

[0010] In a preferred embodiment of the present invention, the living body light measuring device includes a judging means for judging an abnormal part based on a time course of hemoglobin concentration for each measuring part. The biological optical measurement device according to another preferred embodiment of the present invention has a function that the signal processing means calculates the oxygen remaining time in the tissue based on the time course of the hemoglobin concentration.

Since it is possible to know the oxygen residual time in the blood, when performing a treatment or the like corresponding to the amount of oxygen in the blood, the treatment or the like can be performed at the most appropriate time. For example, by knowing the oxygen residual time of the normal tissue and the oxygen residual time of the malignant tumor, the radiation treatment of the malignant tumor selects the most appropriate irradiation timing that minimizes the damage of the normal tissue and maximizes the cell damage of the malignant tumor, Irradiation can be performed.

[0012]

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a perspective view of a living body light measuring device according to an embodiment of the present invention.

FIG. 1 is a block diagram showing an embodiment of a living body light measuring device according to the present invention. The light measuring device mainly includes a light source section 1 for irradiating a subject 9 with light and a subject 9. A light detection unit (photodiode 11 and lock-in amplifier module 12) that detects transmitted light, and controls the driving of the light source unit 1 and the light detection unit, and the biological information of the subject 9 based on the amount of light detected by the light detection unit. And a control unit 17 for performing calculations for creating a topography or the like representing
In the present embodiment, a case is described in which light is applied to a living body from five light irradiation positions using two types of light having different wavelengths, and detection is performed at four light detection positions. The number and the type (number) of emitted light are not limited to these.

The light source unit 1 includes a plurality of optical modules 2 and an oscillating unit 3 for modulating light emitted from each optical module 2.
And an optical fiber 8 connected to each optical module 2. In this embodiment, the number of the optical modules 2 is five in accordance with the light irradiation position.

Each of the optical modules 2 includes two semiconductor lasers, and emits light having different wavelengths in the visible to infrared wavelength range from these two semiconductor lasers. Although the wavelength varies depending on the object to be measured, for example, when measuring a change in hemoglobin, light having two wavelengths of 780 nm and 830 nm is emitted. The light source unit 1 may use a light emitting diode instead of a semiconductor laser.

The oscillating unit 3 is composed of ten oscillators having different oscillating frequencies corresponding to the number of semiconductor lasers of the optical module 2, and applies different modulations to the light generated by the optical module 2, for example, amplitude modulation. .

The two-wavelength light emitted from the optical module 2 is:
The light is guided into one optical fiber, that is, the irradiation optical fiber 8 via an optical fiber coupler (not shown).

The other end of the irradiating optical fiber 8 whose one end is connected to the optical fiber coupler is fixed to a mounting tool (not shown) so as to have a predetermined arrangement together with a detecting optical fiber 10 of a detecting section described later. Attached to the subject. The end faces of these optical fibers are lightly in contact with the surface of the subject, and the other end of the optical fiber 8 for irradiation has different 5
Light emitted from the irradiation position at each location and reflected from the subject is detected by the detection optical fibers 10 arranged at four detection positions on the surface of the subject. The end of the optical fiber attached to the attachment is called a probe.
In addition, a mounting device for mounting an optical fiber on a subject can be formed in various shapes according to an object to be inspected, such as a belt shape or a helmet shape, for example, a living body described in JP-A-9-149903. A known optical measurement device can be used.

FIG. 2 shows an example of the arrangement of the irradiation position and the detection position. In the illustrated example, five irradiation optical fibers 8 are used.
Are shown, and the irradiation positions R1 to R5 are alternately arranged on the square lattice with the detection positions D1 to D4. At this time, assuming that the midpoint between the adjacent irradiation position and the detection position is the measurement position, in this case, since there are 12 combinations of the adjacent irradiation position and the detection position, the number of measurement positions, that is, the number of measurement channels is 12. Become.

The detecting section includes a photodetector 11 for converting an optical signal into an electric signal, and a detecting circuit 1 for selectively detecting a modulated signal.
2 and an A / D converter 16, and the photodetector 11 is connected to each detection optical fiber 10. In the illustrated embodiment, a photodiode is shown as the photodetector 11, but any other photoelectric conversion element such as a photomultiplier tube can be used. In particular, an avalanche photodiode capable of realizing highly sensitive optical measurement is desirable.

In the illustrated embodiment, the detection circuit 12 is a lock-in amplifier module comprising a plurality of lock-in amplifiers and an amplification circuit, and selectively detects a modulation signal corresponding to an irradiation position and a wavelength. In the case of the arrangement of the irradiation position and the detection position shown in FIG. 2, since 12 measurement positions are measured using two wavelengths of light, the number of signals to be measured is 24. Therefore, the lock-in amplifier module uses 24 lock-in amplifiers. However, when using digital modulation,
A digital filter or a digital signal processor is used for detecting the modulation signal. The A / D converter 16
The signal measured by the lock-in amplifier module 12 is converted into a digital signal and sent to the control unit 17.

The control section 17 calculates a digitally converted measurement signal using a recording section 18 for recording the signal measured by the lock-in amplifier module 12 and the calculation result thereof, and a calibration curve of hemoglobin stored in advance. A processing unit 19 that creates a topography and an input / output unit 20 that inputs necessary information such as measurement conditions to the control unit 17 and displays the topography created by the processing unit 19 on a monitor.

The processing unit 19 uses the detected light amounts of the two wavelengths at each measurement position to change the oxygenated hemoglobin concentration change and deoxygenated hemoglobin concentration change accompanying the brain activity, and further, the total hemoglobin concentration as the total amount of these hemoglobin concentrations. Calculate density changes and create topography. This method is described in, for example, Japanese Patent Application Laid-Open No. 9-19408, and will not be described in detail here. Further, the processing unit 19 calculates the time during which oxygen remains in a specific site from the oxygenated hemoglobin concentration change and the deoxygenated hemoglobin concentration change, and specifies whether the site is a malignant tumor based on the remaining time. .

The input / output unit 20 inputs image data measured by another image diagnostic apparatus such as an X-ray CT apparatus or MRI in addition to measurement conditions and the like.
The data formed by the processing unit 19 is displayed on the monitor in parallel with the image or superimposed on the CT image or MR image.

Image data of another image diagnostic apparatus is measured in order to correlate biological light measurement data obtained for each measurement point with a part of a subject.
This is obtained by attaching a probe that can be imaged by another image diagnostic apparatus to a location on the subject corresponding to the measurement point in a state where the probe for measuring biological light is mounted on the subject. As a marker, a metal foil such as an aluminum foil, a metal sphere, or a contrast agent can be used in the case of X-ray CT, and a fat-soluble drug such as vitamin E or a contrast agent can be used in the case of MRI.

Next, an embodiment in which the living body optical measurement device having the above configuration is applied to the diagnosis of a malignant tumor in the brain under an oxygen load will be described, particularly focusing on the processing of the processing unit 19. 3 and 4 show processing steps of the processing unit 19.

Probes having the arrangement shown in FIG. 2 are mounted on the left and right sides of the subject's head, and light is generated from the light source unit 1 and radiated from the light irradiation position. To detect. The signal processor calculates the amount of oxygenated hemoglobin and the amount of deoxygenated hemoglobin from the amounts of light of both wavelengths by simultaneous equations (step 301).
This calculation is performed for each channel (measurement point). Step 301 is continuously performed to create graphs in which the amount of oxygenated hemoglobin and the amount of deoxygenated hemoglobin are plotted on the time axis, respectively, and displayed on the monitor via the input / output unit 20 (step 302). Such a measurement is started before oxygen inhalation, and a value measured before oxygen inhalation is used as a base value. Thereafter, an oxygen load is given by, for example, oxygen inhalation for two minutes, and a change in the amount of hemoglobin is monitored.

FIG. 5A shows an example of a graph displayed on the monitor. As shown, the graph is displayed for 12 measurement points for each of the right brain and the left brain. In the illustrated example, the case where the number of measurement points is small and a graph of all the measurement points is displayed is shown. However, when the number of measurement points is as large as several tens or 100 or more, some of the measurement points, for example, It is also possible to display a graph only for a part determined to be abnormal by the processing.

FIGS. 5B to 5D show graphs of the left brain measurement points P3 and P7 and the right brain measurement point P10 among the measurement points in FIG. 5A, respectively. As shown in the graph at measurement point P7 in the left brain, the oxygenated hemoglobin level in normal tissues rapidly increased after oxygen load and then returned to the original value, whereas the oxygen load in malignant tumor (measurement point P10) increased. After that, oxygen remains for a relatively long time. In addition, in the part where the function is reduced (measurement point P3), the rise after the oxygen load is small, and the manner of the decrease is gradual. From the characteristics of these graphs, it is possible to determine a malignant tumor site or a site with reduced function.

However, skill is required to determine a malignant tumor from such a graph. Therefore, in the present embodiment, the determination is automatically made by the processing unit 19. That is, the processing unit 19
Determines which measurement point is a malignant tumor based on the above-mentioned temporal change in the amount of hemoglobin at each measurement point. Therefore, the elapsed time after the oxygen load is counted (step 30).
3) After a certain period of time, an average of the amount of oxygenated hemoglobin up to a predetermined time before that is calculated (304). Then, it is determined whether or not the average value is equal to or larger than a threshold value (for example, a base value) (305). If the average value is equal to or larger than the threshold value, a mark indicating a malignant tumor is set in the corresponding channel (306).

The time when the process proceeds from step 303 to step 304 is a time when a predetermined time (t) has passed from the time when oxygenated hemoglobin returns to the original value (base value) in a normal tissue. It is known that the time required for oxygenated hemoglobin in normal tissue to return to the original value (base value) after oxygen loading is about 2 minutes, and here 3 minutes (t = 3) elapse. The time is set to 5 minutes. This time can be appropriately changed according to the sex, age, etc. of the subject, and can be set from the input / output unit 20. The calculation of the hemoglobin amount is averaged for the predetermined time t.

In this case, a base value can be used as the threshold value in step 305, but a base + αd (d is a variance of a value before applying an oxygen load, and α is a coefficient, for example, 3) is taken into consideration in consideration of an error of the apparatus. It is practical to do. This threshold can also be set from the input / output unit 20.

With this setting, the value for the past three minutes after the lapse of 5 minutes for a normal tissue is approximately the base value, whereas the oxygen retention time is long for a malignant tumor. Therefore, after 5 minutes have passed after 2 minutes,
Oxygenated hemoglobin shows a higher value than the base value. Therefore, it is possible to determine that the tumor is a malignant tumor in step 305.

The above steps 301 to 306 are performed for all the channels, and it is determined whether or not each measurement point is a malignant tumor. In the embodiment shown in FIG. 3, the case where the malignant tumor is judged by calculating the past oxygenated hemoglobin value after the lapse of a predetermined time has been described, but the deoxygenated hemoglobin value or the difference between them may be used. Good. Further FIG.
The area surrounded by the oxygenated hemoglobin curve and the deoxygenated hemoglobin curve in the graph shown in (1) (integral value in a certain time range) may be calculated, and it may be determined whether or not this area is equal to or larger than a predetermined value.

As described above, for example, a characteristic change in hemoglobin, which is different from that of normal tissue, such as a slow rise of oxygen inhalation, is also observed in a function-deteriorated site. Is also possible. In this case, for example, when the oxygenated hemoglobin amount after a predetermined time immediately after oxygen inhalation is equal to or less than a predetermined value, it is possible to determine that the function is deteriorated, and the integrated value from immediately after inhalation to the predetermined time is equal to or less than a predetermined value. It may also be determined whether or not. The determination flow of the function-decreasing part can be added to the flow shown in FIG.

Next, a description will be given of the association between a measurement point determined to be a malignant tumor or functional deterioration and a site. Hereinafter, a case of a malignant tumor for simplicity will be described.

Upon completion of the above-described processing steps for each measurement point, the processing section 19 creates a topography based on a known method (401). In the topography, for example, a region containing a large amount of oxygen is represented by red, and a region containing a small amount of oxygen is represented by a change in color tone as blue. Such topography is created, for example, at each of two time points before the oxygen load and after a certain period of time after the load, and is displayed together with the measurement time.

Next, in step 306, the measurement point at which the malignant tumor mark is set is set by displaying a specific mark or color on the topography (402), and the topography to which the malignant tumor mark is attached is displayed, for example, as shown in FIG. As shown in FIG. 6, the image is superimposed and displayed on a diagnostic image of another image diagnostic device input from the input / output unit 20 (403). In this case, since the images of the respective measurement points of the biological optical measurement device are also displayed in the diagnostic image as described above (not shown in FIG. 6), these measurement points and the measurement points of the topography overlap. By enlarging or reducing the topography as described above, it is possible to accurately overlap the topography. In this case, for example, a malignant tumor site can be specified while confirming the site of the diagnostic image by displaying the diagnostic image in black-and-white gradation and displaying the topography in a color tone such as red or blue. Alternatively, only the measurement points at which the malignant tumor mark is set in the topography may be displayed in color tone and superimposed on the diagnostic image. Further, when calculating a dose in a radiation treatment to be described later using image data, the CT can be accurately calculated by using a black and white value indicating a CT value.

As described above, since the malignant tumor site is specified on the diagnostic image, highly reliable diagnosis can be performed together with other information obtained from the diagnostic image.

As described above, the function of the processing section of the living body optical measurement device is provided with a function of displaying a temporal change in the amount of hemoglobin at each measurement point, thereby specifying a portion where an abnormality has occurred. Thus, biological information that is very effective for diagnosis can be extracted in an easy-to-understand manner. In particular, by providing a function of automatically determining an abnormal part from a difference in temporal change of each part, it is possible to easily determine and display an abnormal part without requiring skill.

In this embodiment, in order to correlate the living body light measurement data with the part of the subject, an image is taken by another diagnostic imaging apparatus with the living body light measurement probe attached, and this data is taken. Has been explained, but MR
After separately performing imaging by I or CT and measurement of living body light, it is also possible to superimpose optical topography on MR images or CT images using a three-dimensional input device, for example, a neuronavigator.

In the above embodiment, the case where the topography in which the malignant tumor mark is set is superimposed and displayed on the diagnostic image is described. Such a method is most effective for diagnosis, but the display method is not limited to this. Instead, for example, the topography and the diagnostic image may be displayed side by side on a monitor. In this case, the diagnostician can specify the site while comparing the position of the measurement point of the biological optical measurement device shown in the diagnostic image with the topography.

The embodiment in which the living body optical measurement device of the present invention is applied to the diagnosis of a malignant tumor in the brain under an oxygen load has been described. Next, an embodiment in which the biological optical measurement device of the present invention is applied to radiation treatment of a malignant tumor will be described.

As described above, in the radiation treatment of malignant tumors, it is known that a high therapeutic effect can be obtained by applying an oxygen load to the tumor tissue and irradiating radiation while oxygen is retained. In this embodiment, based on this finding, the oxygen residual time in a malignant tumor is detected and used for radiotherapy.

FIG. 7 is a diagram showing an outline of a radiotherapy system incorporating the living body light measuring device of the present invention. The living body light measuring device 71 and an imaging device for taking a photograph for treatment and simulating the treatment. It comprises a simulation device, here a CT device 72, a treatment device 73 for irradiating radiation such as a microtron, and an oxygen inhaler 74.

The operation of this system will be described with reference to FIG. First, using the oxygen inhaler 74, the biological optical measurement device 7
The measurement according to 1 is performed to identify the malignant tumor site of the patient, and to measure the oxygen residual time when the oxygen is loaded (steps 801 and 802). The measurement of the oxygen retention time is performed for each of the normal site and the malignant tumor site. The procedure of each oxygen residual time measurement will be described later. To identify the malignant tumor site,
As in the above-described embodiment, the decrease in the amount of oxygenated hemoglobin is monitored, and if it does not return to the base value after a certain period of time, it is determined that the tumor is a malignant tumor. It is set on the image taken by the device 72 (step 803). However, in this case, instead of transferring or inputting the image of the CT device 72 to the living body optical measurement device 71, information of the measurement point determined to be a malignant tumor is sent to the CT device 72, and the CT device 72 side To set a malignant tumor mark at the corresponding measurement point.

The CT device 72 uses the image data captured by CT to generate an image (DR) viewed from the radiation beam of the treatment device.
R image) are synthesized and displayed (804). The operator looks at this image and simulates the dose calculation to determine the optimum irradiation field and number of gates (805). The CT device 72 controls the irradiation field shape control parameter MLC (Mul
ti Leaf Collimeter) is transmitted to the treatment apparatus 73 as a digital signal (806).

After the above preparations are completed, the CT device 7
While looking at the malignant site displayed in Step 2, a treatment center (isocenter) mark is attached to the corresponding site of the patient, and the isocenter of the treatment apparatus is aligned with the mark site of the patient (80).
7). Oxygen inhalation is started, and irradiation is performed after the elapse of the oxygen retention time of the normal tissue from that time until the oxygen retention time of the malignant tumor (808).

FIG. 9 shows an example of a procedure for measuring the oxygen remaining time in the processing section 19. FIG. 9 shows a procedure for measuring the oxygen residual time for a malignant tumor site. This process is performed between a measurement point determined as a malignant site and a measurement point determined as a normal site by the process illustrated in FIG. Do for both.
In the flow of FIG. 9, steps 902 to 904 are the same as steps 303 to 305 of FIG. 3, and an average value of oxygenated hemoglobin values in the past, for example, about one minute is obtained at each set relatively short time. It is determined whether or not the value is within + 3d. When the average value falls within the base value + 3d, the earliest time point (time from the oxygen load to the time point) of the averaged time points is set as the oxygen residual time (906). When there are a plurality of measurement points determined to be a malignant tumor or a normal site, it is desirable to perform the above-described processing for a plurality of measurement points and take an average thereof.

The start of the irradiation of the therapeutic device 73 is determined by using the oxygen remaining time for the normal part among the oxygen remaining times thus obtained, and the oxygen remaining time of the malignant tumor tissue is determined to be the end of the irradiation. Thus, radiation treatment can be performed within the most effective time in which oxygen remains.

In this embodiment, the case where the oxygen remaining time is obtained in advance by measuring the biological light and the start and end timings of the radiotherapy are determined based on the obtained time is described.
By using a material that does not reflect or absorb radiation as a mounting tool of the living body light measurement device, the living body light measurement device can be used as a monitor for radiation therapy. That is, it is also possible to perform treatment when the malignant tumor site is at an appropriate radiation irradiation timing while monitoring the residual oxygen concentration while performing oxygen inhalation with the living body optical measurement device mounted.

Further, in this embodiment, both the identification of the malignant tumor site and the oxygen remaining time in the malignant tumor tissue are performed by the living body light measuring device 71. Alternatively, the diagnosis may be performed by another diagnostic apparatus in combination with or in combination with.

[0053]

According to the living body light measuring device of the present invention, the means for displaying the time course of the hemoglobin concentration at each of a plurality of measurement points is provided, so that the behavior of the hemoglobin concentration over time differs from that of normal tissue. The indicated malignant tumor can be determined in relation to the site. In addition, since the oxygen residual time in the malignant tumor can be calculated from the lapse of the hemoglobin amount, an appropriate irradiation timing can be set for the radiation of the malignant tumor. In particular, by incorporating information obtained by the biological optical measurement device of the present invention into a therapeutic or diagnostic image obtained by another diagnostic device,
Irradiation to the malignant tumor site becomes easy.

[Brief description of the drawings]

FIG. 1 is a block diagram showing an embodiment of a biological light measurement device according to the present invention.

FIG. 2 is a diagram showing an embodiment of an arrangement of light irradiation positions and detection positions.

FIG. 3 is a flowchart showing one embodiment of the operation of the biological light measurement device of the present invention.

FIG. 4 is a flowchart of an operation following the flow of FIG. 3;

FIG. 5 is a diagram showing an example of a time course of hemoglobin concentration displayed by the living body light measurement device of the present invention.

FIG. 6 is a diagram showing an example of a time course of hemoglobin concentration displayed by the biological light measurement device of the present invention.

FIG. 7 is a conceptual diagram showing one embodiment of a radiotherapy system incorporating the living body light measurement device of the present invention.

FIG. 8 is a flowchart showing an embodiment in which the biological optical measurement device of the present invention is applied to radiation therapy.

FIG. 9 is a flowchart showing an example of a procedure for calculating an oxygen remaining time by the biological light measurement device of the present invention.

[Explanation of symbols]

 1 light source unit 2 optical module 11 photodiode (light detection unit) 12 lock-in amplifier module (light detection unit) 17 control Unit 19: Processing unit 20: Input / output unit

 ────────────────────────────────────────────────── ─── Continuing from the front page (72) Inventor Shunichiro Fujimoto 180-1 F-term (reference) 2G045 AA13 CA25 CB01 DA51 FA11 FA13 FA34 GC10 GC30 JA01 JA04 JA07 4C038 KK01 KL05 KL07 KM00 KX01 KX02

Claims (3)

[Claims] 1. A light irradiating means for irradiating a living body with light modulated differently from a plurality of light irradiating positions, and a relationship between the light irradiating positions by detecting light transmitted through the living body at a plurality of detecting positions. For a plurality of measurement sites determined by, a light detection unit that outputs an electric signal corresponding to the detected light amount, a signal processing unit that calculates the hemoglobin concentration for each measurement site based on the electric signal from the light detection unit, A biological light measurement device comprising: means for displaying a calculation result of a signal processing means; wherein the display means comprises means for displaying a lapse of time of the hemoglobin concentration for each measurement site. apparatus. 2. The living body light measuring device according to claim 1, wherein said signal processing means includes a judging means for judging an abnormal part based on a lapse of time of said hemoglobin concentration for each measurement part. 3. The living body light measurement device according to claim 1, wherein said signal processing means calculates an oxygen remaining time in the tissue based on a lapse of time of said hemoglobin concentration.